GlassScriptPhysician profile
Jessica M Reader
NPI 1508328915
$3,943.18
in general payments reported to CMS, 2019-2025
46 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,158 · 2022: $968 · 2023: $1,034 · 2024: $440 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,817.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $737.07 | 2021-2024 | |
| Novo Nordisk INC | $483.78 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Genzyme Corporation | $180.61 | 2021-2023 | |
| Corium, LLC | $174.99 | 2023 | Adlarity |
| Ucb, INC. | $153.74 | 2021-2023 | Briviact |
| Biohaven Pharmaceuticals, INC. | $147.44 | 2021 | |
| Jazz Pharmaceuticals INC. | $132.70 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $131.92 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $126.71 | 2021-2023 | Austedo, Airduo Digihaler |
| Novartis Pharmaceuticals Corporation | $118.81 | 2021-2024 | |
| Exact Sciences Corporation | $116.60 | 2023-2025 | Cologuard Collection Kit |
| Celgene Corporation | $107.19 | 2022-2023 | Zeposia |
| Astrazeneca Pharmaceuticals LP | $88.30 | 2022 | |
| Eisai INC. | $85.08 | 2021 | |
| Amgen INC. | $84.68 | 2022-2025 | Otezla, Repatha |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Reader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.